JP2019089834A5 - - Google Patents

Download PDF

Info

Publication number
JP2019089834A5
JP2019089834A5 JP2019026743A JP2019026743A JP2019089834A5 JP 2019089834 A5 JP2019089834 A5 JP 2019089834A5 JP 2019026743 A JP2019026743 A JP 2019026743A JP 2019026743 A JP2019026743 A JP 2019026743A JP 2019089834 A5 JP2019089834 A5 JP 2019089834A5
Authority
JP
Japan
Prior art keywords
apoe mimetic
treatment cycle
pharmaceutical composition
rest period
apoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026743A
Other languages
English (en)
Japanese (ja)
Other versions
JP6772317B2 (ja
JP2019089834A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019089834A publication Critical patent/JP2019089834A/ja
Publication of JP2019089834A5 publication Critical patent/JP2019089834A5/ja
Application granted granted Critical
Publication of JP6772317B2 publication Critical patent/JP6772317B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026743A 2013-03-14 2019-02-18 アポリポタンパク質模倣体及びその使用 Expired - Fee Related JP6772317B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US61/782,956 2013-03-14
US201361834992P 2013-06-14 2013-06-14
US61/834,992 2013-06-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016502527A Division JP6570511B2 (ja) 2013-03-14 2014-03-14 アポリポタンパク質模倣体及びその使用

Publications (3)

Publication Number Publication Date
JP2019089834A JP2019089834A (ja) 2019-06-13
JP2019089834A5 true JP2019089834A5 (enExample) 2019-10-31
JP6772317B2 JP6772317B2 (ja) 2020-10-21

Family

ID=51581312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502527A Expired - Fee Related JP6570511B2 (ja) 2013-03-14 2014-03-14 アポリポタンパク質模倣体及びその使用
JP2019026743A Expired - Fee Related JP6772317B2 (ja) 2013-03-14 2019-02-18 アポリポタンパク質模倣体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016502527A Expired - Fee Related JP6570511B2 (ja) 2013-03-14 2014-03-14 アポリポタンパク質模倣体及びその使用

Country Status (12)

Country Link
US (1) US20160002315A1 (enExample)
EP (1) EP2996706B1 (enExample)
JP (2) JP6570511B2 (enExample)
AU (2) AU2014239186B2 (enExample)
BR (1) BR112015022624A2 (enExample)
CA (1) CA2903869A1 (enExample)
DK (1) DK2996706T3 (enExample)
ES (1) ES2753381T3 (enExample)
IL (1) IL240787B (enExample)
MX (1) MX2015012818A (enExample)
NZ (1) NZ713291A (enExample)
WO (1) WO2014152776A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
MA44234B1 (fr) * 2016-02-17 2023-10-31 Regeneron Pharma Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EA201891979A1 (ru) 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
WO2023018876A2 (en) * 2021-08-11 2023-02-16 The Regents Of The University Of California Barrier function preserving peptides for membranes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2697957A1 (en) * 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CN102917727B (zh) * 2010-01-06 2017-10-17 康石医药科技(上海)有限公司 Apoe肽及其用途
CA2954475C (en) * 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Similar Documents

Publication Publication Date Title
JP2019089834A5 (enExample)
JP2009530395A5 (enExample)
JP2010529128A5 (enExample)
JP2014521684A5 (enExample)
JP2013509435A5 (enExample)
JP2010540654A5 (enExample)
BRPI0716261A2 (pt) composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
JP2015520188A5 (enExample)
JP2010518079A5 (enExample)
JP2009541373A5 (enExample)
KR20140095479A (ko) 비염의 치료
JP2015524802A5 (enExample)
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
JP2016515137A5 (enExample)
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
JP2018531945A (ja) 免疫系を刺激するためのペプチドの使用
CA2470656A1 (en) Corticotropin releasing factor 2 receptor agonists
JP2020528903A5 (enExample)
JPH06507386A (ja) 治療用ペプチド
JP2018515459A (ja) 自己免疫障害及び炎症障害を治療及び/又は予防するための短い合成ペプチド
JP7353973B2 (ja) Apoc-ii模倣ペプチド
JP2004513079A5 (enExample)
CA2902619A1 (en) Methods for treating multiple sclerosis
US20200172587A1 (en) Hydrochloride salts of c5a receptor agonist peptides
JP2020531586A5 (enExample)